Orphazyme wins prestigious Entrepreneur of the Year award in the Life Science category
Founder and CSO, Thomas Kirkegaard Jensen was proud to receive the award on behalf of the company at the annual Ernst & Young gala show this week in Copenhagen; an award that recognizes innovative projects with significant potential.
”This award is a validation of our research in the orphan and neglected disease area and supports our ambition of providing much needed therapies to patients worldwide", says Thomas Kirkegaard Jensen.
Orphazyme recently announced that the company is in the final preparation stages for a Phase II/III registration-enabling clinical trial in Niemann-Pick disease type C with Arimoclomol, a small molecule inducer of heat shock protein. "This is a busy but exciting time for our hardworking employees who are devoted to providing new high quality therapeutic options to patients suffering from devastating degenerative diseases and their families. To our team, the EY award is a much welcomed motivation and an acknowledgement of their hard work and commitment", says CEO Anders Hinsby.
Read the EY news release here
Anders Hinsby, CEO of Orphazyme
Orphazyme ApS is a Danish biopharmaceutical company, which develops paradigm-changing medicines for the treatment of genetic diseases. The lead program is in preclinical development as treatment for lysosomal storage diseases. This family of genetic disorders consists of more than 45 diseases, most of which are currently untreatable and often fatal. Orphazyme has raised more than 17 million euro in seed and series A financing, from a strong investor base which includes Novo Ventures, Sunstone Capital and Aescap Venture. For more information, please visit www.orphazyme.com.